Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Reports Sharply Improved 2019 Second Quarter Financial ResultsAugust 12, 2019

Net Revenues Increase 128% Year-Over-Year, as FDA-Approved Treatment for Sickle Cell Disease Rolls Out

Emmaus Life Sciences Reiterates Financial Benefits from Recent MergerAugust 08, 2019

Company to Announce Second Quarter Financial Results Next Week

Emmaus Life Sciences Details Financial Benefits from Recent Merger, including Improved Balance Sheet and Reduced Debt ServiceJuly 29, 2019

Company to Appeal Nasdaq Staff’s Determination

Emmaus Life Sciences Brings “Sideline Sickle Cell” Campaign to Dallas for Participation in Annual Warriors ConventionJuly 24, 2019

Campaign spokesperson Solomon Wilcots and Senior Vice President of Research and Development for Emmaus, Charles Stark, Pharm.D., will lead an informative presentation at the event’s Young Adult Reception.

Emmaus Life Sciences Receives Notice of Nasdaq Delisting Following Merger with MYnd AnalyticsJuly 22, 2019

Emmaus to Appeal Nasdaq Staff’s Determination